| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Elongation of very long chain fatty acids protein 3, 3-keto acyl-CoA synthase ELOVL3, Cold-inducible glycoprotein of 30 kDa, ELOVL fatty acid elongase 3, ELOVL FA elongase 3, Very-long-chain 3-oxoacyl-CoA synthase 3, ELOVL3, CIG30 |
| Entrez GeneID | 83401 |
| WB Predicted band size | 31.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ELOVL3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 241-270 amino acids from the C-terminal region of human ELOVL3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ELOVL3(C-term)抗体的3篇参考文献，按文献名称、作者和摘要内容概括整理：
1. **"Role of ELOVL3 in Hepatic Lipid Metabolism: Insights from a Polyclonal Antibody Targeting the C-Terminal Domain"**
*作者：Zhang et al.*
**摘要**：研究通过制备针对ELOVL3 C端的多克隆抗体，验证了其在肝脏组织中的特异性表达。实验表明，ELOVL3通过调节极长链脂肪酸的合成，影响小鼠肝脏脂质代谢，抗体在Western blot和免疫组化中表现出高特异性。
2. **"ELOVL3 Deficiency Alters Skin Barrier Function via Dysregulated Ceramide Synthesis"**
*作者：Matsuzaka et al.*
**摘要**：文章利用C端特异性抗体研究ELOVL3在小鼠表皮中的功能，发现其缺失导致神经酰胺合成减少，皮肤屏障受损。抗体成功用于免疫荧光定位，证实ELOVL3在角质细胞中的表达模式。
3. **"Development and Validation of an Anti-ELOVL3 (C-Terminal) Monoclonal Antibody for Obesity-Related Metabolic Studies"**
*作者：Li et al.*
**摘要**：研究团队开发了一种针对ELOVL3 C端的单克隆抗体，并验证其在肥胖模型小鼠脂肪组织中的应用。结果显示，ELOVL3在高脂饮食诱导的脂肪肝中表达上调，抗体为代谢综合征研究提供了可靠工具。
---
**备注**：以上文献信息为示例性内容，实际文献可能需要通过PubMed或Web of Science等数据库检索。如需具体文章，建议结合关键词“ELOVL3 C-terminal antibody”进一步筛选。
The ELOVL3 (C-term) antibody is designed to target the C-terminal region of the ELOVL3 (Elongation of Very Long Chain Fatty Acids-Like 3) protein, a member of the ELOVL family of enzymes critical for fatty acid elongation. ELOVL3 specifically catalyzes the synthesis of very long-chain fatty acids (VLCFAs) and polyunsaturated fatty acids (PUFAs), playing a key role in lipid metabolism, skin barrier formation, and thermoregulation. It is highly expressed in tissues such as the liver, brown adipose tissue, and skin, where it contributes to the production of lipids essential for cellular membrane integrity and energy storage.
This antibody is commonly used in research to study ELOVL3's expression, localization, and function in metabolic and dermatological contexts. By binding to the C-terminal epitope, it enables detection of endogenous ELOVL3 via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Its specificity is often validated through knockout controls or siRNA-mediated protein knockdown. Research applications include investigating disorders linked to lipid dysregulation, such as obesity, diabetes, and ichthyosis, as well as exploring ELOVL3's role in adaptive thermogenesis and sebum production. The antibody's utility extends to both preclinical models and human tissue studies, aiding in the elucidation of molecular mechanisms underlying metabolic syndromes and epidermal pathologies.
×
